Bank of New York Mellon
SYRS

Bank of New York Mellon’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bank of New York Mellon’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,645
Closed -$25K – 4609
2022
Q2 		$25K Sell
2,645
-16,387
-86% -$153K ﹤0.01% 4473
2022
Q1 		$227K Sell
19,032
-373
-2% -$6.67K ﹤0.01% 4176
2021
Q4 		$633K Sell
19,405
-210
-1% -$8.5K ﹤0.01% 3648
2021
Q3 		$876K Buy
19,615
+930
+5% +$45.4K ﹤0.01% 3467
2021
Q2 		$1.02M Buy
18,685
+3,949
+27% +$234K ﹤0.01% 3412
2021
Q1 		$1.1M Buy
14,736
+1,122
+8% +$117K ﹤0.01% 3275
2020
Q4 		$1.48M Sell
13,614
-795
-6% -$72.5K ﹤0.01% 3021
2020
Q3 		$1.27M Sell
14,409
-496
-3% -$56.4K ﹤0.01% 2973
2020
Q2 		$1.59M Buy
14,905
+3,229
+28% +$290K ﹤0.01% 2814
2020
Q1 		$692K Buy
11,676
+540
+5% +$36.6K ﹤0.01% 3215
2019
Q4 		$770K Sell
11,136
-11
-0.1% -$667 ﹤0.01% 3364
2019
Q3 		$1.16M Buy
11,147
+556
+5% +$52.5K ﹤0.01% 3082
2019
Q2 		$981K Buy
10,591
+2,266
+27% +$158K ﹤0.01% 3223
2019
Q1 		$761K Sell
8,325
-129
-2% -$8.98K ﹤0.01% 3338
2018
Q4 		$470K Buy
8,454
+689
+9% +$52.3K ﹤0.01% 3518
2018
Q3 		$925K Buy
7,765
+706
+10% +$81.9K ﹤0.01% 3313
2018
Q2 		$720K Buy
7,059
+1,900
+37% +$235K ﹤0.01% 3432
2018
Q1 		$670K Buy
5,159
+1,637
+46% +$179K ﹤0.01% 3435
2017
Q4 		$343K Sell
3,522
-11
-0.3% -$1.48K ﹤0.01% 3758
2017
Q3 		$520K Buy
3,533
+531
+18% +$99.9K ﹤0.01% 3572
2017
Q2 		$483K Buy
3,002
+1,838
+158% +$289K ﹤0.01% 3616
2017
Q1 		$185K Buy
+1,164
New +$142K ﹤0.01% 3900

Other funds holding SYRS

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Bank of New York Mellon's SYRS Position: Q3 2022 in Review

Bank of New York Mellon sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 2,645 shares — an estimated $25K sold.

Bank of New York Mellon first reported a position in SYRS in Q1 2017 and held it in 22 quarters. The position peaked at $1.59M in Q2 2020. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • Bank of New York Mellon reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 2,645 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $25K.
  • Bank of New York Mellon first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 22 quarters.
  • Bank of New York Mellon's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.59M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.